<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069094</url>
  </required_header>
  <id_info>
    <org_study_id>ZN-001</org_study_id>
    <nct_id>NCT01069094</nct_id>
  </id_info>
  <brief_title>A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata</brief_title>
  <official_title>A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of 3 doses of Progenta versus placebo versus Lucron Depot for treatment of
      leiomyomata.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three doses of Progenta (CDB4124 - 12.5, 25, 50 mg) versus placebo versus Lucron Depot
      (leuprolide acetate for depot suspension) was initiated in females with symptomatic
      leiomyomata. A single dose PK visit was conducted only for subjects randomized to the
      Progenta arm, between screening and visit 1. A second PK assessment was conducted at Visit 3
      (one month on drug) to collect steady state data. Treatment period lasted for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of Progenta when administered in pre-menopausal women with symptomatic leiomyomata.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the tolerability of three doses of Progenta (12.5 mg, 25 mg, and 50 mg) as compared to placebo and Lucron Depot (leuprolide acetate for depot suspension) in pre-menopausal women with symptomatic leiomyomata.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Uterine Leiomyomata</condition>
  <arm_group>
    <arm_group_label>progenta 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progenta (CDB-4124) 12.5 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progenta 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progenta (CDB-4124) 25 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progenta 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progenta (CDB-4124) 50 mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucron Depot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucron Depot, Leuprolide acetate for depot suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progenta</intervention_name>
    <description>12.5 mg, administered as a once daily oral dose for 90 days.</description>
    <arm_group_label>progenta 12.5 mg</arm_group_label>
    <other_name>CDB-4124</other_name>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progenta</intervention_name>
    <description>25 mg, administered as a once daily oral dose for 90 days.</description>
    <arm_group_label>progenta 25 mg</arm_group_label>
    <other_name>CDB-4124</other_name>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progenta</intervention_name>
    <description>50 mg, administered as a once daily oral dose for 90 days.</description>
    <arm_group_label>progenta 50 mg</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucron Depot</intervention_name>
    <description>3.75 mg IM monthly</description>
    <arm_group_label>Lucron Depot</arm_group_label>
    <other_name>leuprolide acetate for depot suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as a once daily oral dose for 90 days.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had at least one leiomyomata lesion that was identifiable and measurable by
             transvaginal ultrasound.

          -  Had a regular or steady menstrual cycle lasting from 24 to 36 days.

        Exclusion Criteria:

          -  Post-menopausal

          -  Subject with documented endometriosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Wiehle, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University /MTZ Clinical Research Sp.zo.o.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

